ECG
Everus Construction Group, Inc.
ECG's fundamentals are strong and it looks cheap: trading at 15x earnings, below its usual 25x. Analysts expect strong earnings growth, though they disagree widely on how much.
EOSE
Eos Energy Enterprises, Inc.
There isn't enough reported data to score EOSE yet.
ECG Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Healthy |
ECG's revenue, profitability, cash flow and balance sheet are all currently healthy.
EOSE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EOSE's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ECG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $87.17 | — |
| Current | 15x | $87.17 | — |
| Cheap | 20x | $113 | +29% |
| Fair | 25x | $142 | +63% |
| Expensive | 31x | $174 | +100% |
Historical ranges are pointers, not guarantees.
ECG's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
EOSE PE Valuation
EOSE has no meaningful PE right now: it lost money over the past year.
ECG Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ECG, with profitability improving. However, they disagree widely on these estimates.
EOSE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect EOSE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ECG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.68 | +18% |
| Q3 2026 | $5.66 | +60% |
| Q2 2026 | $4.98 | +53% |
| Q1 2026 | $4.37 | +47% |
| Q4 2025 | $3.95 | +35% |
| Q3 2025 | $3.54 | +37% |
| Q2 2025 | $3.25 | +31% |
| Q1 2025 | $2.98 | +20% |
| Q4 2024 | $2.92 | +19% |
ECG has the stronger earnings trend. Trailing diluted EPS is up 60% for ECG versus EOSE down 224%.
EOSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.69 | +$0.85 |
| Q2 2023 | -$3.76 | -$1.00 |
| Q1 2023 | -$3.65 | -$0.86 |
| Q4 2022 | -$3.68 | -$1.32 |
| Q3 2022 | -$3.54 | +$5.19 |
EOSE is still losing money, but less than at its worst: $4.55 per share over the past year, against $8.73 at its worst in late 2021.
ECG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +40% |
| Q2 2026 | $1.2B | +34% |
| Q1 2026 | $1B | +25% |
| Q4 2025 | $1B | +33% |
| Q3 2025 | $986.8M | +30% |
| Q2 2025 | $921.5M | +31% |
| Q1 2025 | $826.6M | +32% |
| Q4 2024 | $759.6M | +19% |
ECG's revenue has grown year over year for nine quarters in a row: $1.4B last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.8% | +1.5 points |
| Q2 2026 | 9.1% | +1.2 points |
| Q1 2026 | 7.5% | +1.3 points |
| Q4 2025 | 6.8% | +0.8 points |
| Q3 2025 | 7.3% | +0.3 points |
| Q2 2025 | 7.9% | +0.6 points |
| Q1 2025 | 6.2% | 0 points |
| Q4 2024 | 6.1% | -2 points |
ECG has the edge over EOSE on profitability, with a higher operating margin.
EOSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $82.7M | +171% |
| Q2 2026 | $68.8M | +351% |
| Q1 2026 | $57M | +445% |
| Q4 2025 | $58M | +700% |
| Q3 2025 | $30.5M | +3473% |
| Q2 2025 | $15.2M | +1597% |
| Q1 2025 | $10.5M | +58% |
| Q4 2024 | $7.3M | +9.7% |
EOSE has the edge over ECG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -96% | +105 points |
| Q2 2026 | -122% | +297 points |
| Q1 2026 | -139% | +367 points |
| Q4 2025 | -140% | +573 points |
| Q3 2025 | -201% | +6044 points |
| Q2 2025 | -419% | +2815 points |
| Q1 2025 | -506% | +117 points |
| Q4 2024 | -713% | -74 points |
EOSE's operating margin was −96% last quarter, up 105 points from the same quarter a year ago, near the top of its range since 2019.
ECG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $52.7M | -20% |
| Q2 2026 | $33M | +169% |
| Q1 2026 | $128.2M | +$139.6M |
| Q4 2025 | $23.5M | -65% |
| Q2 2025 | $12.3M | +$37.7M |
| Q1 2025 | -$11.4M | -190% |
| Q4 2024 | $66.9M | -35% |
| Q2 2024 | -$25.4M | -$6M |
ECG has the edge over EOSE on cash generation, producing positive trailing cash flow while its opponent burns cash.
EOSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$105.1M | -$22.4M |
| Q2 2026 | -$107.4M | -$34.3M |
| Q1 2026 | -$154.8M | -$121M |
| Q4 2025 | -$75.2M | -$19.5M |
| Q3 2025 | -$82.7M | -$28.5M |
| Q2 2025 | -$73.2M | -$40.6M |
| Q1 2025 | -$33.8M | +$10.7M |
| Q4 2024 | -$55.8M | -$10.2M |
EOSE has burned cash in almost every quarter: −$443M over the past year, against −$246M the year before.
ECG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +19K shares |
| 1 year | +0.2% | +102K shares |
| 3 years | +0.5% | +267K shares |
ECG has the edge over EOSE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
EOSE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +63% | +213M shares |
| 1 year | +161% | +341M shares |
| 3 years | +888% | +497M shares |
EOSE has 553M diluted shares, up 161% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
ECG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2024 | 1.5x | Healthy |
| Q1 2024 | 0.0x | Very low |
| Q4 2023 | 0.9x | Very low |
ECG's net debt is less than a year of its operating earnings (EBITDA).
EOSE Net Leverage
EOSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ECG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 15.6 | Oversold |
ECG's weekly RSI is 36 (neutral) and its Stochastic is 16 (oversold).
EOSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.4 | Oversold |
EOSE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ECG PE vs Industrials Sector
| Metric | ECG | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 24x | 36% below |
| PE % | 9 | 30 | 21 pts below |
ECG is trading at 15x earnings, a 36% discount to the Industrials sector's median of 24x.
EOSE PE vs Industrials Sector
EOSE has no meaningful PE right now: it lost money over the past year.
ECG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.2 | 16% below |
| 20 week MA | $118.5 | 26% below |
| 50 week MA | $119.1 | 27% below |
| 100 week MA | $92.3 | 5.5% below |
EOSE has stronger trend alignment. ECG is above 0 of 4 weekly averages versus EOSE above 0 of 5.
EOSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 19% below |
| 20 week MA | $3.28 | 45% below |
| 50 week MA | $7.01 | 74% below |
| 100 week MA | $7.10 | 75% below |
| 200 week MA | $4.53 | 60% below |
EOSE is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
ECG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $52.5 | $69.9 | +33% |
| 2025 | $69.9 | $90.1 | +29% |
| 2026 YTD | $90.1 | $87.2 | -3.2% |
ECG has the edge over EOSE on returns for 2026, with the stronger performance.
EOSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.72 | $19.2 | +98% |
| 2021 | $19.2 | $8.57 | -55% |
| 2022 | $8.57 | $1.08 | -87% |
| 2023 | $1.08 | $1.09 | +0.9% |
| 2024 | $1.09 | $5.17 | +374% |
| 2025 | $5.17 | $11.9 | +129% |
| 2026 YTD | $11.9 | $1.81 | -85% |
EOSE's yearly returns have swung widely, from +374% in 2024 to −87% in 2022. It's down 85% so far in 2026.